Skip to main content
Top
Published in: Diabetology International 1/2022

01-01-2022 | Glimepiride | Case Report

Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence

Authors: Shunsuke Tominari, Megumi Yasuda, Takehiro Kato, Mayu Sakai, Sodai Kubota, Kenta Nonomura, Tokuyuki Hirose, Ken Takao, Yanyan Liu, Masami Mizuno, Takuo Hirota, Katsumi Iizuka, Tetsuya Suwa, Yukio Horikawa, Daisuke Yabe

Published in: Diabetology International | Issue 1/2022

Login to get access

Abstract

Background

Elderly adults with diabetes are at increased risk of severe hypoglycemia and hypoglycemic coma due to various conditions including decline in cognitive function, reduced activity of daily living (ADL) and reduced renal function; special cautions are, therefore, recommended to avoid these life-threatening events.

Case presentation

A 92-year-old female was admitted to our institution because of severe coma. Upon arrival, her serum C-peptide was 1.64 ng/mL despite low plasma glucose (24 mg/dL) and serum glimepiride (40.85 ng/mL). She had past history of compression fracture of her lumbar spine, which substantially affected her ADL. Her score on the dementia assessment sheet for community-based integrated care system-8 items (DASC-8) was 26 points. She had been receiving 12 oral medications for diabetes, essential hypertension, chronic gastritis and constipation from her nearby clinic. Her physician-in-charge had found that she was not taking her medications properly and simplified her prescription regimen to 3 oral medications with vildagliptin 50 mg twice daily replaced by glimepiride 3 mg once daily and asked her son to assist in taking the drugs 6 days before her admission to our hospital. While her consciousness level was improved to some extent, she was transferred to a long-term care bed hospital because it had become too difficult to care for her at home.

Conclusions

It is important to note that anti-diabetes drugs should be carefully selected based on each patient’s cognitive function and ADL, and that the reasoning should be shared with the general practitioners involved to avoid severe hypoglycemic events.
Appendix
Available only for authorised users
Literature
1.
go back to reference Report C. Glycemic targets for elderly patients with diabetes: Japan diabetes society (JDS)/Japan geriatrics society (JGS) Joint committee on improving care for elderly patients with diabetes. J Diabetes Investig. 2017;8(1):126–8.CrossRef Report C. Glycemic targets for elderly patients with diabetes: Japan diabetes society (JDS)/Japan geriatrics society (JGS) Joint committee on improving care for elderly patients with diabetes. J Diabetes Investig. 2017;8(1):126–8.CrossRef
2.
go back to reference Japan Diabetes Society /Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with D, Haneda M, Ito H. Glycemic targets for elderly patients with diabetes. Diabetol Int. 2016;7(4):331–3.CrossRef Japan Diabetes Society /Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with D, Haneda M, Ito H. Glycemic targets for elderly patients with diabetes. Diabetol Int. 2016;7(4):331–3.CrossRef
3.
go back to reference Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315(10):1034–45.CrossRef Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315(10):1034–45.CrossRef
4.
go back to reference Fushiki Y, Kinoshita K, Tokuda Y. Polypharmacy and adverse drug events leading to acute care hospitalization in japanese elderly. General Medicine. 2014;15(2):110–6.CrossRef Fushiki Y, Kinoshita K, Tokuda Y. Polypharmacy and adverse drug events leading to acute care hospitalization in japanese elderly. General Medicine. 2014;15(2):110–6.CrossRef
5.
go back to reference Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12(3):425–30.CrossRef Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12(3):425–30.CrossRef
6.
go back to reference Toyoshima K, Araki A, Tamura Y, Iritani O, Ogawa S, et al. Development of the dementia assessment sheet for community-based integrated care system 8-items, a short version of the dementia assessment sheet for community-based integrated care system 21-items, for the assessment of cognitive and daily functions. Geriatr Gerontol Int. 2018;18(10):1458–62.CrossRef Toyoshima K, Araki A, Tamura Y, Iritani O, Ogawa S, et al. Development of the dementia assessment sheet for community-based integrated care system 8-items, a short version of the dementia assessment sheet for community-based integrated care system 21-items, for the assessment of cognitive and daily functions. Geriatr Gerontol Int. 2018;18(10):1458–62.CrossRef
7.
go back to reference Namba M, Iwakura T, Nishimura R, Akazawa K, Matsuhisa M, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. J Diabetes Investig. 2018;9:642.CrossRef Namba M, Iwakura T, Nishimura R, Akazawa K, Matsuhisa M, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. J Diabetes Investig. 2018;9:642.CrossRef
8.
go back to reference Namba M, Iwakura T, Nishimura R, Akazawa K, Matsuhisa M, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. Diabetol Int. 2018;9(2):84–99.CrossRef Namba M, Iwakura T, Nishimura R, Akazawa K, Matsuhisa M, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. Diabetol Int. 2018;9(2):84–99.CrossRef
9.
go back to reference Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507–15.CrossRef Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507–15.CrossRef
10.
go back to reference Witsch J, Neugebauer H, Flechsenhar J, Juttler E. Hypoglycemic encephalopathy: a case series and literature review on outcome determination. J Neurol. 2012;259(10):2172–81.CrossRef Witsch J, Neugebauer H, Flechsenhar J, Juttler E. Hypoglycemic encephalopathy: a case series and literature review on outcome determination. J Neurol. 2012;259(10):2172–81.CrossRef
11.
go back to reference Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, et al. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes Metab. 2017;19(3):442–7.CrossRef Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, et al. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes Metab. 2017;19(3):442–7.CrossRef
12.
go back to reference Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, et al. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >/= 60 years (START-J trial). Diabetes Obes Metab. 2017;19(8):1188–92.CrossRef Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, et al. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >/= 60 years (START-J trial). Diabetes Obes Metab. 2017;19(8):1188–92.CrossRef
13.
go back to reference Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.CrossRef Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.CrossRef
14.
go back to reference Deerochanawong C, Chandraprasert S, Suthijumroon A, Vichayanrat A, Himathongkam T, et al. Glimepiride in type 2 diabetes mellitus Thai patients. J Med Assoc Thai. 2001;84(9):1221–8.PubMed Deerochanawong C, Chandraprasert S, Suthijumroon A, Vichayanrat A, Himathongkam T, et al. Glimepiride in type 2 diabetes mellitus Thai patients. J Med Assoc Thai. 2001;84(9):1221–8.PubMed
15.
go back to reference Araki E, Goto A, Kondo T, Noda M, Noto H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165–223.CrossRef Araki E, Goto A, Kondo T, Noda M, Noto H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165–223.CrossRef
16.
go back to reference Araki E, Goto A, Kondo T, Noda M, Noto H, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11(4):1020–76.CrossRef Araki E, Goto A, Kondo T, Noda M, Noto H, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11(4):1020–76.CrossRef
Metadata
Title
Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence
Authors
Shunsuke Tominari
Megumi Yasuda
Takehiro Kato
Mayu Sakai
Sodai Kubota
Kenta Nonomura
Tokuyuki Hirose
Ken Takao
Yanyan Liu
Masami Mizuno
Takuo Hirota
Katsumi Iizuka
Tetsuya Suwa
Yukio Horikawa
Daisuke Yabe
Publication date
01-01-2022
Publisher
Springer Singapore
Published in
Diabetology International / Issue 1/2022
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-021-00510-9

Other articles of this Issue 1/2022

Diabetology International 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine